Possible synergies between isatin, an endogenous MAO inhibitor, and antiparkinsonian agents on the dopamine release from striatum of freely moving rats.

Faro, L.R.F.; Justo, Lorenzo; Alfonso, Miguel Ángel Martínez; Durán, R.

doi:10.1016/j.neuropharm.2020.108083

Cited by 5 publications

(9 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study was carried out with female rats. Previous data from our laboratory did not show significant differences between males and females both in baseline dopamine levels and in the effects observed by the intrastriatal administration of different treatments (Alfonso et al, 2003;Arias et al, 1998;Faro et al, 2020;Justo et al, 2016). Furthermore, in a recent systematic review by Egenrieder et al (2020), these authors also did not observe significant differences between males and females; neither relates to the basal levels of dopamine found in the striatum nor the effects produced by the administration of drugs of abuse.…”

Section: Methodsmentioning

confidence: 59%

“…A study from our laboratory showed that intrastriatal infusion of isatin increases the levels of striatal dopamine in a concentration‐dependent manner, being this increase dependent on the depolarization of the dopaminergic terminal as well as dependent on the presence of Ca ++ in the extracellular medium, and also dependent on the storage of dopamine in the synaptic vesicles (Justo et al., 2016). Furthermore, we have recently proven that the administration of isatin together with antiparkinsonian drugs significantly improves the extracellular levels of striatal dopamine, showing that, in addition to its effect as a MAO inhibitor, it can also act as a dopamine releaser (Faro et al., 2020).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Participation of glutamatergic and nitrergic systems in the striatal dopamine release induced by isatin, a MAO inhibitor

Faro

Justo

Gómez

et al. 2021

Eur J of Neuroscience

Self Cite

View full text Add to dashboard Cite

Isatin is a biofactor with different biochemical and pharmacological properties whose effects attract much attention because it is an endogenous inhibitor of the monoamine oxidase in the brain. When exogenously administrated, isatin increases dopamine levels in intact and denervated striatum of rats, an effect that could indicate its potential as a therapeutic agent in Parkinson disease. However, the neurochemical mechanisms by which isatin increases dopamine in the striatum are poorly understood. In the present study, we evaluate the role of the glutamatergic and nitrergic systems in the isatin‐induced dopamine release from rat striatum. Our findings show that the intrastriatal administration of 10 mM isatin significantly increases the in vivo release of dopamine (1,104.7% ± 97.1%), and the amino acids glutamate (428.7% ± 127%) and taurine (221% ± 22%) from rat striatum measured by brain microdialysis. The pretreatment with MK‐801 (500 µM) or AP5 (650 µM) (glutamatergic NMDA receptors antagonists) significantly reduces the effect of isatin on dopamine release by 52% and 70.5%, respectively. The administration of the nitric oxide synthase inhibitors, L‐NAME (100 µM) or 7‐NI (100 µM) also decreases the isatin‐induced dopamine release by 77% and 42%, respectively. These results show that isatin, in addition to increasing dopamine release, also increases glutamate levels, and possibly activates NMDA receptors and nitric oxide production, which can promote a further increase in the dopamine release.

show abstract

Section: Methodsmentioning

confidence: 59%

Section: Introductionmentioning

confidence: 99%

Participation of glutamatergic and nitrergic systems in the striatal dopamine release induced by isatin, a MAO inhibitor

Faro

Justo

Gómez

et al. 2021

Eur J of Neuroscience

Self Cite

View full text Add to dashboard Cite

show abstract

“…There have been experiments in which a MAO inhibitors in combination with existing Parkinsonian combatant substances (including caffeine) yields "increased extracellular dopamine levels in the striatum" in rats (Faro, Justo, Alfonso, & Duran, 2020). Further rat studies showed similar results as far as a combination of MAO inhibition and caffeine resulting in neuroprotective effects (Kasabova-Angelova et al, 2020).…”

Section: Coffee and Tea -Monoamine Oxidase Inhibitionmentioning

confidence: 97%

A review of the primary nutritional and environmental factors associated with Parkinson’s disease

Considine

Yin²,

Hartmann³

2021

J Stud Res

View full text Add to dashboard Cite

Parkinson’s disease is a progressive nervous system disorder that produces both motor and nonmotor symptoms. This literature review begins by examining evidence for several possible origins for the disease: does it begin in the brain and progress to the gut, or vice versa, or does it begin in both places concurrently? Next, we examine several environmental factors that have been shown to either increase or decrease risk of Parkinson’s disease. These are primarily nutritional factors, specifically caffeine, nicotine, and dairy products. Studies in both animals and humans provide weak evidence that increased consumption of low fat dairy is associated with an increased risk of Parkinson’s disease development. Additionally, there is strong evidence that nicotine has a neuroprotective effect which also lowers the risk. Finally, there is similarly strong evidence that caffeine exerts neuroprotective effects which lower the overall risk of developing Parkinson’s disease.

show abstract

“…Teniendo en cuenta que la isatina es un compuesto endógeno y sus niveles son más altos en pacientes con EP, la isatina podría interaccionar con los fármacos antiparkinsonianos administrados al paciente. Además, la isatina también puede atenuar los efectos de otros agentes farmacológicos en objetivos específicos como MAO o compuestos neuroprotectores (10).…”

unclassified

“…De este modo, la coadministración de isatina con inhibidores de la catecol-O-metiltransferasa (COMT), amantadina, L-DOPA y cafeína incrementa los niveles de dopamina estriatal de forma aditiva. Únicamente se describe ausencia de efectos sinérgicos en la coadministración de isatina con el agonista dopaminérgico ropinirol (10).…”

unclassified

Isatina, un compuesto endógeno a considerar en la Enfermedad de Parkinson

Justo-Cousiño

Faro

Durán

2021

Rev Peru Investig Salud

Self Cite

View full text Add to dashboard Cite

show abstract

Possible synergies between isatin, an endogenous MAO inhibitor, and antiparkinsonian agents on the dopamine release from striatum of freely moving rats.

Cited by 5 publications

References 54 publications

Participation of glutamatergic and nitrergic systems in the striatal dopamine release induced by isatin, a MAO inhibitor

Participation of glutamatergic and nitrergic systems in the striatal dopamine release induced by isatin, a MAO inhibitor

A review of the primary nutritional and environmental factors associated with Parkinson’s disease

Isatina, un compuesto endógeno a considerar en la Enfermedad de Parkinson

Contact Info

Product

Resources

About